Drug Characteristics
  • Formulation

    Inhalation powder: 5 mg/dose

  • Dose

    Influenza A (IAV) treatment second line :

    10 mg twice a day (two puffs) by disk inhaler for 5 days

    Post-exposure prophylaxis:

    10 mg once a day for 10 days

  • Side Effects

    Very rarely, bronchospasm respiratory impairment, angioedema, urticaria, and rash

  • Interactions

    Limited data. Low potential for drug interactions

  • Renal

    No dosage reduction for inhalational formulation

  • Hepatic

    No data on dosage reduction in patients with hepatic dysfunction

  • Pregnancy

    Compatible – Maternal Benefit >> Embryo-Foetal Risk

  • Other Information